PT  - JOURNAL ARTICLE
AU  - Utsunomiya, Yuri Tani
AU  - Utsunomiya, Adam Taiti Harth
AU  - Torrecilha, Rafaela Beatriz Pintor
AU  - de Cássia Paula, Silvana
AU  - Milanesi, Marco
AU  - Fernando Garcia, José
TI  - Growth rate and acceleration analysis of the COVID-19 pandemic reveals the effect of public health measures in real time
AID  - 10.1101/2020.03.30.20047688
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.03.30.20047688
4099  - http://medrxiv.org/content/early/2020/04/02/2020.03.30.20047688.short
4100  - http://medrxiv.org/content/early/2020/04/02/2020.03.30.20047688.full
AB  - We used moving regression to model the growth rate (cases/day) and acceleration (cases/day2) of COVID-19 cases in 123 countries as of March 25th 2020. In countries entering stationary growth (China and South Korea) decline in acceleration was observable up to 1 week after severe restriction to human mobility was adopted as a preventive measure. Deceleration was detectable within 2 weeks, whereas stationary growth was reached within 6 weeks. These results corroborate that mass social isolation is a highly effective measure against the dissemination of SARS-CoV-2. We also found that the impact of public health measures could be evaluated in seemingly real-time by monitoring COVID-19 growth curves. Moreover, reasonable daily predictions of new cases were obtained (R2 ∼ 0.95). Apart from the analysis of prevalence partitioned by country, moving regression can be easily applied to city, state, region or arbitrary territory data to help monitoring the local behavior of COVID-19 cases.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis study does not involve clinical trialsFunding StatementThis study did not receive financial supportAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data in this study was obtained from the European Center for Disease Prevention and Control (ECDC) and is publicly available at https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-geographic-disbtribution-worldwide-2020-03-25.xlsx (accessed on March 25th 2020). The source code for the Shiny App used for data analysis is found in our GitHub repository: https://github.com/adamtaiti/SARS-CoV-2. https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-geographic-disbtribution-worldwide-2020-03-25.xlsx https://github.com/adamtaiti/SARS-CoV-2